NASDAQ:OVID
Ovid Therapeutics Inc Stock News
$3.15
-0.125 (-3.82%)
At Close: May 17, 2024
What being stricken with Covid-19 taught a biotech CEO - STAT
08:55am, Thursday, 11'th Jun 2020
Apellis CEO Cedric François describes what it was like to have Covid-19 and try to manage a company with active clinical trials through a global pandemic.
A pandemic, a funeral, and a chance to help heal the world - STAT
08:50am, Thursday, 11'th Jun 2020
People tend to negotiate with themselves when faced with difficult situations. I did that with the start of the Covid-19 pandemic.
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced the addition of two partners to its Global Corporate Social Res
Molecular Templates: Updates To Thesis, Pursuing Validated Targets With Unique MOA (NASDAQ:MTEM)
07:07am, Wednesday, 10'th Jun 2020
Shares have risen by 157% since my 2018 recommendation and by 127% since my September update. Near term events include AACR II presentation (present new ETB pro
Takeda Pharmaceutical Co Ltd (NYSE:TAK) Shares Sold by Rockefeller Capital Management L.P.
06:36am, Wednesday, 10'th Jun 2020
Rockefeller Capital Management L.P. lessened its stake in Takeda Pharmaceutical Co Ltd (NYSE:TAK) by 85.5% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 2,614 sh
7 Pharmaceutical Stocks to Buy for Post-Pandemic Gains
03:49pm, Tuesday, 09'th Jun 2020
Much of the conversation about pharmaceutical stocks rests on the coronavirus, but these high-growth names have potential beyond the pandemic.
Ewing Sarcoma Drugs Market 2020 Clinical Survey Report – Merck, Roche, GlaxoSmithKline, Novartis, Pfizer, Johnson & Johnson
10:43am, Tuesday, 09'th Jun 2020
Jun 09, 2020 (Market Insight Reports) --
The Ewing Sarcoma Drugs Market report is a compilation of first-hand information, qualitative and quantitative...
Ovid Therapeutics Announces Multiple Presentations on the 2020 American Academy of Neurology Science Highlights Platform
12:00pm, Monday, 08'th Jun 2020
NEW YORK, June 08, 2020 -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced findings from two new interim analyses of data from the Phase 3 H
Ovid Therapeutics Launches Pipeline Teach-In Webinar Series
01:00pm, Thursday, 04'th Jun 2020
NEW YORK, June 04, Jun 04, 2020 (GLOBE NEWSWIRE via COMTEX) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing...
Ovid Therapeutics Launches Pipeline Teach-In Webinar Series
12:00pm, Thursday, 04'th Jun 2020
Company to host first webinar on Wednesday, June 17, to review OV935 (soticlestat) development program for rare developmental and epileptic encephalopathies (DEE) NEW YORK,.
武田发布Pevonedistat联合阿扎胞苷治疗较高危MDS患者2期试验的有力数据
12:00am, Tuesday, 02'nd Jun 2020
(美国商业资讯)--武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)今天宣布，2期Pevonedistat-2001试验结果将于在线进行的第56届美国临床�
NK Cells Market Professional Survey by Booming Types & Application Report 2020 and Growth Forecasts to 2026
11:48am, Monday, 01'st Jun 2020
Jun 01, 2020 (The Expresswire) --
Global “NK Cells Market” report 2020 is an overview of the market is provided with prime focus on factors boosting and...
歐盟委員會同意武田無需履行從夏爾後續化合物SHP647撤資的承諾
12:00am, Monday, 01'st Jun 2020
(美國商業資訊)-- 武田藥品工業株式會社(Takeda Pharmaceutical Company Limited) (TOKYO:4502) (NYSE:TAK)（「武田」）今天宣佈，歐盟委員會(“EC”)於5月28日解除了武�
En el día de hoy, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) anunció que los resultados del ensayo Pevonedistat-2001 de fase II se pres
